一次遠位中血管閉塞(DMVO)による急性虚血性脳卒中患者におけるiNstroke 4F血栓吸引カテーテルの安全性と有効性の評価 (4-NiVO)
iNstroke 4F血栓吸引カテーテルの、一次遠位中等径血管閉塞(DMVO)による急性虚血性脳卒中患者における有効性および安全性を評価するための前向き単群多施設共同試験。
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.
調査の概要
詳細な説明
This study is an exploratory, interventional, open label, single-arm, multi-centre prospective clinical investigation.
In this post-market clinical investigation, the aim is to further evaluate the efficacy and safety of the iNstroke 4F aspiration catheter, with a view to, in future clinical investigations, comparing the product with the standard therapy or with other similar products. In addition, this clinical investigation will generate results that could be used to further assess the safety and effectiveness of mechanical thrombectomy for the treatment of DMVO.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Barcelona、スペイン
- Hospital Universitario Vall d'Hebron
-
Madrid、スペイン
- Hospital Universitario 12 de Octubre
-
Madrid、スペイン
- Hospital Universitario La Paz
-
Madrid、スペイン
- Hospital Universitario de Getafe
-
Murcia、スペイン
- Hospital Clínico Universitario Virgen de Arrixaca
-
-
-
-
-
Bonn、ドイツ
- Universitätsklinikum Bonn
-
Kiel、ドイツ
- Universitätsklinikum Schleswig-Holstein
-
Marburg、ドイツ
- Klinikum Marburg
-
Nuremberg、ドイツ
- Klinikum Nürnberg
-
Recklinghausen、ドイツ
- Knappschaftskrankenhaus Recklinghausen
-
-
-
-
-
Budapest、ハンガリー
- Semmelweis University Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subjects aged ≥ 18 years.
- Subjects with symptom onset up to 24 hours.
- Isolated primary demonstrated occlusion in a distal medium vessel (Non-dominant or distal M2-MCA segment, M3 or M4 segments of MCA, A2-A3 segments of ACA, P1, P2 and P3 segments of PCA) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
- Baseline NIHSS score ≥5 assessed before the procedure.
- Pre-stroke mRS score ≤ 2.
- Subjects with an ASPECTS score ≥ 6.
- Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).
Exclusion Criteria:
- Subjects aged < 18.
- Suspected secondary DMVO. Suspicion or evidence of primary LVO whether it has been treated or not with fibrinolytic therapy or mechanical thrombectomy that subsequently develops a DMVO.
- Baseline NIHSS score <5 assessed before the procedure.
- Pre-stroke mRS score >2.
- Subjects with an ASPECTS score <6.
- Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
- Severe allergy to contrast media.
- Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
- Medical history of thrombocytopenia (Platelets <100,000).
- Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
- Subjects with occlusions in multiple vessels (e.g., MCA-M3 and ACA-A2), whether or not they undergo mechanical thrombectomy.
- Subjects with cancer (with or without metastases) who have a life expectancy of less than 6 months.
- Subjects participating in a clinical trial at the moment of the inclusion.
- Subjects with pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Thromboaspiration using iNstroke 4F aspiration catheter
No comparator will be used in this clinical investigation as it is an exploratory study of a CE-marked medical device to be used within the scope of its intended purpose. |
Patients to undergo thromboaspiration with iNstroke 4F |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recanalization Endpoint
時間枠:Intra-procedure
|
Recanalization rate with a modified thrombolysis in cerebral infarction scale (mTICI) score ≥2b in ≤3 revascularization passes using iNstroke 4F aspiration catheter, alone or in conjunction with a SR. |
Intra-procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recanalization Endpoint
時間枠:Intra-procedure
|
Proportion of subjects treated with iNstroke 4F alone with complete recanalization in primary DMVO defined as an mTICI ≥2b, after iNstroke 4F aspiration catheter alone (ADAPT) was used as a first-line therapy |
Intra-procedure
|
|
Recanalization Endpoint
時間枠:Intra-procedure
|
Proportion of subjects treated with iNstroke 4F in conjunction with a stent retriever having complete recanalization in primary DMVO defined as achieving an mTICI ≥2b, after iNstroke 4F aspiration catheter, in conjunction with a stent retriever (SR), was used as a first-line therapy. |
Intra-procedure
|
|
Recanalization Endpoint
時間枠:Intra-procedure
|
Proportion of subjects with mTICI≥2b, mTICI≥2c and mTICI 3 after first pass with iNstroke 4F aspiration catheter used both alone and in conjunction with a SR. |
Intra-procedure
|
|
Recanalization Endpoint
時間枠:Intra-procedure
|
Time from groin puncture to achievement of complete recanalization (mTICI ≥2b), or if not achieved, until the final angiogram time, in patients treated with iNstroke 4F aspiration catheter, alone or in conjunction with a SR, as a first-line therapy. |
Intra-procedure
|
|
Recanalization Endpoint
時間枠:Intra-procedure
|
Proportion of subjects in which direct contact with thrombus is achieved with iNstroke 4F aspiration catheter. |
Intra-procedure
|
|
Clinical Endpoint
時間枠:90 day
|
Proportion of subjects achieving a modified Rankin scale (mRS) score of 0-2 at the 90-day (±14 days) post-procedure follow-up visit. |
90 day
|
|
Safety Endpoint
時間枠:24 (-8/+12) hours
|
Occurrence of SICH (according to SITS-MOST (13) and ECASS criteria (14)) within 24 (-8/+12) hours post-procedure, assessed by magnetic resonance imaging (MRI)/computed tomography (CT). Intracerebral Haemorrhage (ICH) is defined as the presence of extravascular blood in the brain or within the skull (local or remote parenchymal hematoma type 2, subarachnoid haemorrhage, and/or intraventricular haemorrhage) detected on the post-procedure imaging scan. ICH is considered symptomatic (SICH) if it is associated with a clinical deterioration, determined by a worsening/increase on the National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points, or if it causes death and is identified as the predominant cause of neurological deterioration. |
24 (-8/+12) hours
|
|
Safety Endpoint
時間枠:Intra-procedure
|
Occurrence of embolization in a previously non-involved (or new) territory as seen on the final control angiogram at the end of the procedure. |
Intra-procedure
|
|
Safety Endpoint
時間枠:Intra-procedure
|
Occurrence of embolization in distal medium territory to the proximal occlusion as seen on the final control angiogram at the end of the procedure. |
Intra-procedure
|
|
Safety Endpoint
時間枠:During hospital admission
|
Inhospital mortality rate related to the procedure during hospital admission. |
During hospital admission
|
|
Safety Endpoint
時間枠:90 days (±14 days) after the procedure.
|
Occurrence of devices and procedure related adverse events within 90 days (±14 days) after the procedure. |
90 days (±14 days) after the procedure.
|
|
Safety Endpoint
時間枠:Intra-procedure
|
Occurrence of procedure-related complications: arterial perforation, arterial dissection and severe vasospasm in the target vessel. |
Intra-procedure
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Exploratory Recanalization Endpoint
時間枠:Intra-procedure
|
Proportion of subjects in which a switch of technique (from ADAPT to combined or from combined to ADAPT) with iNstroke 4F aspiration catheter was used to successfully perform the thrombectomy. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
時間枠:Intra-procedure
|
Proportion of subjects in which an aspiration catheter device with a 4F caliber different from iNstroke 4F aspiration catheter was used as a rescue therapy. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
時間枠:Intra-procedure
|
Proportion of cases in which iNstroke 4F aspiration catheter (alone or in conjunction with a SR) successfully reached the site of occlusion. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
時間枠:Intra-procedure
|
Number of passes with iNstroke 4F aspiration catheter until recanalization. |
Intra-procedure
|
|
Exploratory Recanalization Endpoint
時間枠:Intra-procedure
|
Visibility of the catheter during the thrombectomy rated from 0 to 5 (being 0 the worst and 5 the best score). |
Intra-procedure
|
|
Exploratory Clinical Endpoint
時間枠:24 (-8/+12) hours post-procedure.
|
Proportion of subjects with rapid neurological improvement, defined as a decrease of more than 4 points on the NIHSS scale, during the first 24 (-8/+12) hours post-procedure. |
24 (-8/+12) hours post-procedure.
|
|
Exploratory Clinical Endpoint
時間枠:First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
|
Proportion of subjects with a reduction of ≥8 points on the NIHSS scale during the first 24 (-8/+12) hours post-procedure, or with a NIHSS score of 0-1 at 3 days (±24 hours) or at the time of discharge, whichever occurs first. |
First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
|
|
Exploratory Clinical Endpoint
時間枠:24 (-8/+12) hours.
|
Median of NIHSS score at 24 (-8/+12) hours. |
24 (-8/+12) hours.
|
|
Exploratory Clinical Endpoint
時間枠:3 days (±24 hours) post procedure
|
Median of NIHSS score at 3 days (±24 hours) or at the time of patient discharge, whichever occurs first. |
3 days (±24 hours) post procedure
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。